{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:18:23Z","timestamp":1791818303142,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/leu.2016.287","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T11:29:23Z","timestamp":1476703763000},"page":"1154-1165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1\/RIP3 pathway"],"prefix":"10.1038","volume":"31","author":[{"given":"J","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Breslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cannova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P C","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Nand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A R","family":"Kini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"BFleu2016287_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.2009.22.9088","volume":"28","author":"AK Burnett","year":"2010","unstructured":"Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010; 28: 586\u2013595.","journal-title":"J Clin Oncol"},{"key":"BFleu2016287_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249\u20131259.","journal-title":"N Engl J Med"},{"key":"BFleu2016287_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, Lowenberg B . Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487\u2013494.","journal-title":"J Clin Oncol"},{"key":"BFleu2016287_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/annonc\/mdp309","volume":"21","author":"D Pulte","year":"2010","unstructured":"Pulte D, Gondos A, Brenner H . Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol 2010; 21: 335\u2013341.","journal-title":"Ann Oncol"},{"key":"BFleu2016287_CR5","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1182\/blood-2010-11-283598","volume":"117","author":"SJ Chen","year":"2011","unstructured":"Chen SJ, Zhou GB, Zhang XW, Mao JH, de The H, Chen Z . From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011; 117: 6425\u20136437.","journal-title":"Blood"},{"key":"BFleu2016287_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.molmed.2011.10.001","volume":"18","author":"V Lallemand-Breitenbach","year":"2012","unstructured":"Lallemand-Breitenbach V, Zhu J, Chen Z, de The H . Curing APL through PML\/RARA degradation by As2O3. Trends Mol Med 2012; 18: 36\u201342.","journal-title":"Trends Mol Med"},{"key":"BFleu2016287_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-065X.2012.01108.x","volume":"246","author":"ZJ Chen","year":"2012","unstructured":"Chen ZJ . Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012; 246: 95\u2013106.","journal-title":"Immunol Rev"},{"key":"BFleu2016287_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun SC . Non-canonical NF-kappaB signaling pathway. Cell Res 2011; 21: 71\u201385.","journal-title":"Cell Res"},{"key":"BFleu2016287_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1146\/annurev.biochem.78.070907.102750","volume":"78","author":"B Skaug","year":"2009","unstructured":"Skaug B, Jiang X, Chen ZJ . The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem 2009; 78: 769\u2013796.","journal-title":"Annu Rev Biochem"},{"key":"BFleu2016287_CR10","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.cell.2014.04.019","volume":"157","author":"JA Rickard","year":"2014","unstructured":"Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 2014; 157: 1175\u20131188.","journal-title":"Cell"},{"key":"BFleu2016287_CR11","doi-asserted-by":"publisher","first-page":"14436","DOI":"10.1073\/pnas.1409389111","volume":"111","author":"JE Roderick","year":"2014","unstructured":"Roderick JE, Hermance N, Zelic M, Simmons MJ, Polykratis A, Pasparakis M et al. Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis. Proc Natl Acad Sci USA 2014; 111: 14436\u201314441.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016287_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ni.3206","volume":"16","author":"J Silke","year":"2015","unstructured":"Silke J, Rickard JA, Gerlic M . The diverse role of RIP kinases in necroptosis and inflammation. Nat Immunol 2015; 16: 689\u2013697.","journal-title":"Nat Immunol"},{"key":"BFleu2016287_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature14191","volume":"517","author":"M Pasparakis","year":"2015","unstructured":"Pasparakis M, Vandenabeele P . Necroptosis and its role in inflammation. Nature 2015; 517: 311\u2013320.","journal-title":"Nature"},{"key":"BFleu2016287_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1310050","volume":"370","author":"A Linkermann","year":"2014","unstructured":"Linkermann A, Green DR . Necroptosis. N Engl J Med 2014; 370: 455\u2013465.","journal-title":"N Engl J Med"},{"key":"BFleu2016287_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.beha.2007.11.002","volume":"21","author":"AD Schimmer","year":"2008","unstructured":"Schimmer AD . Apoptosis in leukemia: from molecular pathways to targeted therapies. Best Pract Res Clin Haematol 2008; 21: 5\u201311.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu2016287_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013; 12: 329\u2013341.","journal-title":"Cell Stem Cell"},{"key":"BFleu2016287_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","volume":"12","author":"DJ Goff","year":"2013","unstructured":"Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013; 12: 316\u2013328.","journal-title":"Cell Stem Cell"},{"key":"BFleu2016287_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/cdd.2016.8","volume":"23","author":"Z Su","year":"2016","unstructured":"Su Z, Yang Z, Xie L, DeWitt JP, Chen Y . Cancer therapy in the necroptosis era. Cell Death Differ 2016; 23: 748\u2013756.","journal-title":"Cell Death Differ"},{"key":"BFleu2016287_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcdb.2014.07.013","volume":"35","author":"W Zhou","year":"2014","unstructured":"Zhou W, Yuan J . Necroptosis in health and diseases. Semin Cell Dev Biol 2014; 35: 14\u201323.","journal-title":"Semin Cell Dev Biol"},{"key":"BFleu2016287_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4161\/cbt.26428","volume":"14","author":"S Fulda","year":"2013","unstructured":"Fulda S . The mechanism of necroptosis in normal and cancer cells. Cancer Biol Ther 2013; 14: 999\u20131004.","journal-title":"Cancer Biol Ther"},{"key":"BFleu2016287_CR21","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1128\/MCB.24.4.1464-1469.2004","volume":"24","author":"K Newton","year":"2004","unstructured":"Newton K, Sun X, Dixit VM . Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol 2004; 24: 1464\u20131469.","journal-title":"Mol Cell Biol"},{"key":"BFleu2016287_CR22","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-15-2949","volume":"76","author":"X Jiang","year":"2016","unstructured":"Jiang X, Bugno J, Hu C, Yang Y, Herold T, Qi J et al. Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res 2016; 76: 4470\u20134480.","journal-title":"Cancer Res"},{"key":"BFleu2016287_CR23","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/leu.2010.212","volume":"24","author":"E Weisberg","year":"2010","unstructured":"Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010; 24: 2100\u20132109.","journal-title":"Leukemia"},{"key":"BFleu2016287_CR24","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s10637-010-9475-6","volume":"29","author":"F Servida","year":"2011","unstructured":"Servida F, Lecis D, Scavullo C, Drago C, Seneci P, Carlo-Stella C et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest New Drugs 2011; 29: 1264\u20131275.","journal-title":"Invest New Drugs"},{"key":"BFleu2016287_CR25","doi-asserted-by":"publisher","first-page":"e802","DOI":"10.1038\/cddis.2013.320","volume":"4","author":"L Steinhart","year":"2013","unstructured":"Steinhart L, Belz K, Fulda S . Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013; 4: e802.","journal-title":"Cell Death Dis"},{"key":"BFleu2016287_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrd3627","volume":"11","author":"S Fulda","year":"2012","unstructured":"Fulda S, Vucic D . Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109\u2013124.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2016287_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1084\/jem.20130990","volume":"211","author":"A Volk","year":"2014","unstructured":"Volk A, Li J, Xin J, You D, Zhang J, Liu X et al. Co-inhibition of NF-kappaB and JNK is synergistic in TNF-expressing human AML. J Exp Med 2014; 211: 1093\u20131108.","journal-title":"J Exp Med"},{"key":"BFleu2016287_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nchembio711","volume":"1","author":"A Degterev","year":"2005","unstructured":"Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112\u2013119.","journal-title":"Nat Chem Biol"},{"key":"BFleu2016287_CR29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/cdd.2012.133","volume":"20","author":"A Degterev","year":"2013","unstructured":"Degterev A, Maki JL, Yuan J . Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ 2013; 20: 366.","journal-title":"Cell Death Differ"},{"key":"BFleu2016287_CR30","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1182\/blood-2011-06-359448","volume":"118","author":"Y Xiao","year":"2011","unstructured":"Xiao Y, Li H, Zhang J, Volk A, Zhang S, Wei W et al. TNF-alpha\/Fas-RIP-1-induced cell death signaling separates murine hematopoietic stem cells\/progenitors into 2 distinct populations. Blood 2011; 118: 6057\u20136067.","journal-title":"Blood"},{"key":"BFleu2016287_CR31","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","volume":"137","author":"YS Cho","year":"2009","unstructured":"Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112\u20131123.","journal-title":"Cell"},{"key":"BFleu2016287_CR32","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1172\/JCI111292","volume":"73","author":"ED Ball","year":"1984","unstructured":"Ball ED, Guyre PM, Shen L, Glynn JM, Maliszewski CR, Baker PE et al. Gamma interferon induces monocytoid differentiation in the HL-60 cell line. J Clin Invest 1984; 73: 1072\u20131077.","journal-title":"J Clin Invest"},{"key":"BFleu2016287_CR33","doi-asserted-by":"publisher","first-page":"16448","DOI":"10.1073\/pnas.0607830103","volume":"103","author":"S Xiao","year":"2006","unstructured":"Xiao S, Li D, Zhu HQ, Song MG, Pan XR, Jia PM et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci USA 2006; 103: 16448\u201316453.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016287_CR34","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2012.57","volume":"26","author":"JQ Mi","year":"2012","unstructured":"Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z . How to manage acute promyelocytic leukemia. Leukemia 2012; 26: 1743\u20131751.","journal-title":"Leukemia"},{"key":"BFleu2016287_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.molonc.2013.07.011","volume":"7","author":"J Zhang","year":"2013","unstructured":"Zhang J, Seet CS, Sun C, Li J, You D, Volk A et al. p27 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Mol Oncol 2013; 7: 1069\u20131082.","journal-title":"Mol Oncol"},{"key":"BFleu2016287_CR36","doi-asserted-by":"publisher","first-page":"E3206","DOI":"10.1073\/pnas.1407068111","volume":"111","author":"S McComb","year":"2014","unstructured":"McComb S, Cessford E, Alturki NA, Joseph J, Shutinoski B, Startek JB et al. Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages. Proc Natl Acad Sci USA 2014; 111: E3206\u2013E3213.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016287_CR37","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2014.04.018","volume":"157","author":"CP Dillon","year":"2014","unstructured":"Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 2014; 157: 1189\u20131202.","journal-title":"Cell"},{"key":"BFleu2016287_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/CAD.0b013e32832ced78","volume":"20","author":"DJ Chen","year":"2009","unstructured":"Chen DJ, Huerta S . Smac mimetics as new cancer therapeutics. Anticancer Drugs 2009; 20: 646\u2013658.","journal-title":"Anticancer Drugs"},{"key":"BFleu2016287_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2014.05.007","volume":"144","author":"L Bai","year":"2014","unstructured":"Bai L, Smith DC, Wang S . Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther 2014; 144: 82\u201395.","journal-title":"Pharmacol Ther"},{"key":"BFleu2016287_CR40","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/leu.2014.56","volume":"28","author":"S Fulda","year":"2014","unstructured":"Fulda S . Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities. Leukemia 2014; 28: 1414\u20131422.","journal-title":"Leukemia"},{"key":"BFleu2016287_CR41","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.2008.19.5677","volume":"27","author":"E Dean","year":"2009","unstructured":"Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 2009; 27: 1660\u20131666.","journal-title":"J Clin Oncol"},{"key":"BFleu2016287_CR42","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1200\/JCO.2009.21.8172","volume":"27","author":"AD Schimmer","year":"2009","unstructured":"Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS et al. Phase I\/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009; 27: 4741\u20134746.","journal-title":"J Clin Oncol"},{"key":"BFleu2016287_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10495-010-0545-1","volume":"16","author":"BZ Carter","year":"2011","unstructured":"Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL et al. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1\/2 study of patients with relapsed\/refractory AML. Apoptosis 2011; 16: 67\u201374.","journal-title":"Apoptosis"},{"key":"BFleu2016287_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1309\/AJCPLBK9L9KDYQZP","volume":"137","author":"M Pichler","year":"2012","unstructured":"Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Rehak P et al. Histologic tumor necrosis is an independent prognostic indicator for clear cell and papillary renal cell carcinoma. Am J Clin Pathol 2012; 137: 283\u2013289.","journal-title":"Am J Clin Pathol"},{"key":"BFleu2016287_CR45","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.celrep.2015.02.056","volume":"10","author":"D You","year":"2015","unstructured":"You D, Xin J, Volk A, Wei W, Schmidt R, Scurti G et al. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells. Cell Rep 2015; 10: 2055\u20132068.","journal-title":"Cell Rep"},{"key":"BFleu2016287_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0003489414526368","volume":"123","author":"KK Gallagher","year":"2014","unstructured":"Gallagher KK, Spector ME, Pepper JP, McKean EL, Marentette LJ, McHugh JB . Esthesioneuroblastoma: updating histologic grading as it relates to prognosis. Annals Otol Rhinol Laryngol 2014; 123: 353\u2013358.","journal-title":"Annals Otol Rhinol Laryngol"},{"key":"BFleu2016287_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F . Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361\u2013371.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2016287_CR48","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature 2008; 454: 436\u2013444.","journal-title":"Nature"},{"key":"BFleu2016287_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccell.2016.06.002","volume":"30","author":"U Hockendorf","year":"2016","unstructured":"Hockendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 2016; 30: 75\u201391.","journal-title":"Cancer Cell"},{"key":"BFleu2016287_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/cdd.2011.164","volume":"19","author":"N Vanlangenakker","year":"2012","unstructured":"Vanlangenakker N, Vanden Berghe T, Vandenabeele P . Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19: 75\u201386.","journal-title":"Cell Death Differ"},{"key":"BFleu2016287_CR51","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1038\/cddis.2012.176","volume":"3","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.","journal-title":"Cell Death Dis"},{"key":"BFleu2016287_CR52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature13706","volume":"513","author":"N Takahashi","year":"2014","unstructured":"Takahashi N, Vereecke L, Bertrand MJ, Duprez L, Berger SB, Divert T et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 2014; 513: 95\u201399.","journal-title":"Nature"},{"key":"BFleu2016287_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature13608","volume":"513","author":"M Dannappel","year":"2014","unstructured":"Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513: 90\u201394.","journal-title":"Nature"},{"key":"BFleu2016287_CR54","doi-asserted-by":"publisher","first-page":"31268","DOI":"10.1074\/jbc.M113.462341","volume":"288","author":"WJ Kaiser","year":"2013","unstructured":"Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 2013; 288: 31268\u201331279.","journal-title":"J Biol Chem"},{"key":"BFleu2016287_CR55","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1126\/science.1249361","volume":"343","author":"K Newton","year":"2014","unstructured":"Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343: 1357\u20131360.","journal-title":"Science"},{"key":"BFleu2016287_CR56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.molcel.2014.10.021","volume":"56","author":"P Mandal","year":"2014","unstructured":"Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014; 56: 481\u2013495.","journal-title":"Mol Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016287","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:28:26Z","timestamp":1648744106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFleu2016287"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.287","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]},"assertion":[{"value":"10 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}